Table 1 Active clinical trials targeting CAFs in cancers

NCT02699606

NSCLC, urothelial cancer, gastric cancer, esophageal cancer or cholangiocarcinoma

Erdafitinib

/

A pan- FGFR tyrosine kinase inhibitor

Phase 2

[145]

NCT03762122

Squamous-cell NSCLC

Rogaratinib

/

A pan-FGFR inhibitor

Phase 2

[146]

NCT03386721

Head and neck, oesophageal or cervical cancer

RO6874281

Atezolizumab (MPDL3280A), or Gemcitabine and Vinorelbine

An immunocytokine consisting of IL-2v targeting FAP-α

Phase 2

[147]

NCT02627274

Breast cancer or head and neck cancer

RO6874281

Trastuzumab or Cetuximab

An immunocytokine consisting of IL-2v targeting FAP-α

Phase 1

[148]

NCT03875079

Melanoma

RO6874281

Pembrolizumab

An immunocytokine consisting of IL-2v targeting FAP-α

Phase 1

[149]

NCT03834220

Solid tumors

Debio 1347

/

A pan-FGFR inhibitor

Phase 2

[150]

NCT03822117

Solid tumors

Pemigatinib

/

Targeting activating FGFR mutations or translocations (FIGHT-207)

Phase 2

[151]

NCT02872714

Urothelial cancer

Pemigatinib

/

Tarageting FGF/FGFR alterations (FIGHT-201)

Phase 2

[152]

NCT02924376

Cholangiocarcinoma

Pemigatinib

/

Targeting FGFR2

Phase 2

[153]

NCT02399215

Carcinoid tumor, metastatic carcinoid tumor, or neuroendocrine neoplasm

Nintedanib

/

Blocking VEGFR from attaching to its target

Phase 2

[154]

NCT02834780

Hepatocellular carcinoma

H3B-6527

/

Targeting FGFR4 and FGF19

Phase 1

[155]

NCT03343301

Gastrointestinal cancer

FPA144

mFOLFOX6

Targeting FGFR2

Phase 1

[156]

NCT02432274

Solid malignant tumors or osteosarcoma

Lenvatinib

Ifosfamide, and Etoposide

An inhibitor of VEGFR2 tyrosine kinase with potential antineoplastic activity

Phase 1/2

[157]

NCT02508467

Hepatocellular Carcinoma

Fisogatinib (BLU-554)

/

Targeting FGF19

Phase 1

[158]